肺癌中的线粒体重编程:治疗脆弱性和扭转药物耐药性的战略
1Department of Physiology, Medical School, Jeonbuk National University, Jeonju, Republic of Korea.
线粒体是肺癌进展和耐药性的关键. 用新型抑制剂向线粒体功能障碍显示出克服治疗耐药性和改善非小细胞和小细胞肺癌的结果的希望.
科学领域:
- 线粒体生物学和癌症代谢
- 瘤学和治疗耐药性
- 新型抗癌药物的药理学
背景情况:
- 线粒体现在被理解为癌细胞代谢,信号和生存的中央调节者,而不仅仅是能量生产者.
- 线粒体功能障碍对肺癌 (NSCLC和SCLC) 的发病,进展和治疗耐药性至关重要.
研究的目的:
- 对用于肺癌治疗的线粒体抑制剂的机械学和临床前数据进行审查和综合.
- 为了解肺癌中线粒体向策略提供以证据为基础的框架.
- 突出线粒体抑制剂在克服对现有疗法耐药性的作用.
主要方法:
- 在肺癌中确定线粒体失调的界限,包括代谢重编程.
- 系统地对线粒体抑制剂按作用机制进行分类和分析 (例如,ETC抑制剂,亡调节剂).
- 对临床前数据,临床试验和挑战的审查,包括毒性和生物标志物.
主要成果:
- 肺癌细胞表现出代谢重编程,通常依赖于氧化酸化,呈现出脆弱性.
- 各种线粒体抑制剂 (电子运输链抑制剂,BCL-2/BCL-xL抑制剂,新陈代谢调节剂) 显示出潜力.
- 线粒体抑制剂可以克服对EGFR-TKI,化疗和免疫疗法的获得性抵抗.
结论:
- 针对线粒体的脆弱性提供了一个有希望的策略,以克服肺癌治疗阻力.
- 进一步研究预测生物标志物和管理点上,瘤外毒性对于临床转化至关重要.
- 了解小细胞肺癌的特定弱点对于开发向疗法至关重要.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
Treatment Resistant Cancers
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against...
